Nanjing Blue Shield Biotechnology

Nanjing Blue Shield Biotechnology is a clinical-stage biotechnology company headquartered in Nanjing, China, dedicated to the development of next-generation adoptive cell therapies. The company leverages its proprietary Blue-T platform to engineer CAR-T and TCR-T cells designed to treat a variety of cancers, with a particular emphasis on solid tumors. Their clinical pipeline includes candidates targeting Mesothelin, GPC3, and Claudin 18.2, as well as hematological targets like CD19 and BCMA. By focusing on enhancing cell persistence and overcoming the immunosuppressive tumor microenvironment, Blue Shield Biotech seeks to provide curative options for patients with refractory malignancies.